These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 37342589)

  • 1. A real-world disproportionality analysis of apalutamide: data mining of the FDA adverse event reporting system.
    Fang Z; Xu Z; Zhu W; Yu M; Ji C
    Front Pharmacol; 2023; 14():1101861. PubMed ID: 37342589
    [No Abstract]   [Full Text] [Related]  

  • 2. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system.
    Ji C; Bai J; Zhou J; Zou Y; Yu M
    Br J Clin Pharmacol; 2022 Dec; 88(12):5317-5325. PubMed ID: 35818959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
    Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
    Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
    Shu Y; Chen J; Ding Y; Zhang Q
    Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of triazole antifungals: a pharmacovigilance study from 2004 to 2021 based on FAERS.
    Chai S; Zhan JL; Zhao LM; Liu XD
    Ther Adv Drug Saf; 2022; 13():20420986221143266. PubMed ID: 36545565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Real-World Disproportionality Analysis of Olaparib: Data Mining of the Public Version of FDA Adverse Event Reporting System.
    Shu Y; He X; Liu Y; Wu P; Zhang Q
    Clin Epidemiol; 2022; 14():789-802. PubMed ID: 35789689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database.
    Liu Y; Li H; Hu C; Tan L; Yin P; Li Z; Zhou S; Su L
    Front Pharmacol; 2024; 15():1368244. PubMed ID: 38873427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system.
    Liu M; Gu L; Zhang Y; Zhou H; Wang Y; Xu ZX
    Front Pharmacol; 2024; 15():1290975. PubMed ID: 38357304
    [No Abstract]   [Full Text] [Related]  

  • 12. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
    Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
    Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system.
    Wang K; Wang M; Li W; Wang X
    Front Pharmacol; 2024; 15():1408135. PubMed ID: 38939844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
    Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
    Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
    [No Abstract]   [Full Text] [Related]  

  • 17. A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib.
    Zhang X; Ren X; Zhu T; Zheng W; Shen C; Lu C
    Front Pharmacol; 2024; 15():1407709. PubMed ID: 39114350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.
    Wang J; Zhang A; Ye M; Zhang C
    Front Pharmacol; 2024; 15():1376535. PubMed ID: 38562462
    [No Abstract]   [Full Text] [Related]  

  • 19. Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system.
    Li L; Xu Q; Liu Y; Pang L; Cui Z; Lu Y
    Front Pharmacol; 2024; 15():1403988. PubMed ID: 39114358
    [No Abstract]   [Full Text] [Related]  

  • 20. Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).
    Woods RH
    Br J Clin Pharmacol; 2023 Aug; 89(8):2386-2395. PubMed ID: 36321844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.